Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, OK 73019, United States of America.
Department of Biology, University of Central Oklahoma, 100 North University Drive, Edmond, OK 73034, United States of America.
Biochim Biophys Acta Biomembr. 2023 Aug;1865(6):184172. doi: 10.1016/j.bbamem.2023.184172. Epub 2023 May 17.
Bacterial infections caused by Gram-negative pathogens, such as those in the family Enterobacteriaceae, are among the most difficult to treat because effective therapeutic options are either very limited or non-existent. This raises serious concern regarding the emergence and spread of multi-drug resistant (MDR) pathogens in the community setting; and thus, creates the need for discovery efforts and/or early-stage development of novel therapies for infections. Our work is directed towards branched polyethylenimine (BPEI) modified with polyethylene glycol (PEG) as a strategy for targeting virulence from Gram-negative bacterial pathogens. Here, we neutralize lipopolysaccharide (LPS) as a barrier to the influx of antibiotics. Data demonstrate that the β-lactam antibiotic oxacillin, generally regarded as ineffective against Gram-negative bacteria, can be potentiated by 600 Da BPEI to kill some Escherichia coli and some Klebsiella pneumoniae. Modification of 600 Da BPEI with polyethylene glycol (PEG) could increase drug safety and improves potentiation activity. The ability to use the Gram-positive agent, oxacillin, against Gram-negative pathogens could expand the capability to deliver effective treatments that simplify, reduce, or eliminate some complicated treatment regimens.
革兰氏阴性病原体(如肠杆菌科)引起的细菌感染是最难治疗的感染之一,因为有效的治疗选择非常有限或不存在。这引起了人们对社区环境中多药耐药(MDR)病原体的出现和传播的严重关注;因此,需要进行发现工作和/或针对感染的新型疗法的早期开发。我们的工作旨在针对分枝状聚乙烯亚胺(BPEI)进行修饰,使其与聚乙二醇(PEG)结合,作为靶向革兰氏阴性细菌病原体毒力的策略。在这里,我们通过中和脂多糖(LPS)作为抗生素流入的屏障来实现这一目标。数据表明,β-内酰胺类抗生素苯唑西林通常被认为对革兰氏阴性菌无效,但可以通过 600Da 的 BPEI 增强作用来杀死一些大肠杆菌和一些肺炎克雷伯菌。用聚乙二醇(PEG)修饰 600Da 的 BPEI 可以提高药物安全性并提高增效活性。使用革兰氏阳性药物苯唑西林对抗革兰氏阴性病原体的能力可以扩大有效治疗的能力,从而简化、减少或消除一些复杂的治疗方案。